Implanted Ultrasound Device Opening Blood-Brain Barrier Promising in Brain Tumors
(MedPage Today) -- Use of a novel skull-implantable ultrasound device was able to open the blood-brain barrier, which allowed for penetration of albumin-bound paclitaxel into critical regions of the brain in patients with glioblastoma, a dose-escalation... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 3, 2023 Category: Hematology Source Type: news
Nab-Paclitaxel Does Not Increase Overall Survival in Biliary Tract Cancer
MONDAY, Jan. 23, 2023 -- For patients with biliary tract cancer (BTC), no significant improvement is observed in overall survival with the addition of albumin-bound paclitaxel to gemcitabine and cisplatin (GAP) versus gemcitabine/cisplatin (GC),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 23, 2023 Category: Pharmaceuticals Source Type: news
FDA Warning Letter Cites Abraxane Manufacturing Sterility Issues FDA Warning Letter Cites Abraxane Manufacturing Sterility Issues
The warning follows an FDA inspection at the Phoenix-based Abraxis BioScience plant that found contamination hazards in its manufacturing process.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 16, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Albumin-Bound Paclitaxel Plus Carboplatin for Lung SCC Albumin-Bound Paclitaxel Plus Carboplatin for Lung SCC
Is this regimen a safe and effective option for the neoadjuvant treatment of potentially resectable lung squamous cell carcinoma?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 1, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Abraxane Still in Short Supply for Cancer Patients Abraxane Still in Short Supply for Cancer Patients
Abraxane, an albumin-bound form of paclitaxel used in the treatment of several cancers, is in short supply because of manufacturing delays.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 25, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Actuate Therapeutics Announces Primary Endpoint Met In Phase 2 Study...
Elraglusib Results in 57% Disease Control Rate and 39% Objective Response Rate in Combination with Gemcitabine/Abraxane in First Line Treatment of Pancreatic Cancer(PRWeb October 28, 2021)Read the full story at https://www.prweb.com/releases/actuate_therapeutics_announces_primary_endpoint_met_in_phase_2_study_in_pancreatic_cancer/prweb18295347.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 28, 2021 Category: Pharmaceuticals Source Type: news
Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer
Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test. Roche made this decision following consultation with the US FDA, based on the agency’s assessment of the current mTNBC treatme...
Source: Roche Investor Update - August 27, 2021 Category: Pharmaceuticals Source Type: news
Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer
Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test. Roche made this decision following consultation with the US FDA, based on the agency’s assessment of the current mTNBC treatme...
Source: Roche Media News - August 27, 2021 Category: Pharmaceuticals Source Type: news
Ukrainian Traffickers Sentenced for Counterfeit Cancer and Hepatitis Drugs
FDA OCI, Maksym Nienadov, Healthy Nation, Volodymyr Nikolaienko, Ukraine, counterfeit drug, smuggling, misbranded medicine, Keytruda, Abraxane, Epclusa, cancer, hepatitis C, oncology drug, undercover purchase, custody, prescription drugs, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - March 25, 2021 Category: Medical Law Authors: DOJ Source Type: news
Abraxane (paclitaxel protein-bound particles)
Title: Abraxane (paclitaxel protein-bound particles)Category: MedicationsCreated: 10/28/2020 12:00:00 AMLast Editorial Review: 10/28/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 28, 2020 Category: Cancer & Oncology Source Type: news
Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche ' s Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address challenges a...
Source: Roche Media News - September 19, 2020 Category: Pharmaceuticals Source Type: news
Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche ' s Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address challenges a...
Source: Roche Investor Update - September 19, 2020 Category: Pharmaceuticals Source Type: news
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to results ...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to results ...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news
Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoint of O...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news
